Scheduling of radiation and chemotherapy for limited-stage small-cell lung cancer: Repopulation as a cause of treatment failure?

Journal of Clinical Oncology

Volumn 24, Issue 7, 2006, Pages 1020-1022

  Brade, Anthony M ^a   Tannock, Ian F ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CETUXIMAB; IMATINIB;

BREAST CANCER; CANCER SURVIVAL; CANCER THERAPY; CLINICAL TRIAL; EDITORIAL; HEAD AND NECK CARCINOMA; HUMAN; LUNG SMALL CELL CANCER; LYMPHOMA; OUTCOME ASSESSMENT; PATIENT CARE; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; TREATMENT FAILURE; TREATMENT OUTCOME; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; CONTROLLED CLINICAL TRIAL; DRUG ADMINISTRATION; DRUG EFFECT; LUNG TUMOR; METHODOLOGY; NOTE; RADIATION DOSE FRACTIONATION; RADIATION EXPOSURE; RANDOMIZED CONTROLLED TRIAL; SMALL CELL CARCINOMA; TUMOR EMBOLISM;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SMALL CELL; CHEMOTHERAPY, ADJUVANT; DOSE FRACTIONATION; DRUG ADMINISTRATION SCHEDULE; HUMANS; LUNG NEOPLASMS; NEOADJUVANT THERAPY; NEOPLASM CIRCULATING CELLS; RADIOTHERAPY, ADJUVANT; RANDOMIZED CONTROLLED TRIALS; TREATMENT FAILURE;

EID: 33644986064     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.04.9676     Document Type: Editorial

References (16)

1. De Ruysscher D, Pijls-Johannesma M, Bentzen SM, et al: Time between the first day of chemotherapy and the last day of chest radiation is the most important predictor of survival in limited-disease small-cell lung cancer. J Clin Oncol 24:1052-1056, 2006
2. Kim JJ, Tannock IF: Repopulation of cancer cells during therapy: An important cause of treatment failure. Nat Rev Cancer 5:516-525, 2005
3. Tannock IF: Treatment of cancer with radiation and drugs. J Clin Oncol 14:3156-3174, 1996
4. Withers HR, Taylor JM, Maciejewski B: The hazard of accelerated tumor clonogen repopulation during radiotherapy. Acta Oncol 27:131-146, 1988
5. Murray N, Coy P, Pater JL, et al: Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer: The National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 11:336-344, 1993
6. Jeremic B, Shibamoto Y, Acimovic L, et al: Initial versus delayed accelerated hyperfractionated radiation therapy and concurrent chemotherapy in limited small-cell lung cancer: A randomized study. J Clin Oncol 15:893-900, 1997
7. Turrisi AT, Kim K, Blum R, et al: Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med 340:265-271, 1999
8. Takada M, Fukuoka M, Kawahara M, et al: Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small-cell lung cancer: Results of the Japan Clinical Oncology Group Study 9104. J Clin Oncol 20:3054-3060, 2002
9. James L, Spiro S, O'Donnell, KM, et al: A randomized study of timing of thoracic irradiation in small cell lung cancer (SCLC): Study 8. Lung Cancer 41:S23, 2003 (suppl 2)
10. Jaffray DA: Emergent technologies for 3-dimensional image-guided radiation delivery. Semin Radiat Oncol 15:208-216, 2005
11. Bentzen SM, Atasoy BM, Daley FM, et al: Epidermal growth factor receptor expression in pretreatment biopsies from head and neck squamous cell carcinoma as a predictive factor for a benefit from accelerated radiation therapy in a randomized controlled trial. J Clin Oncol 23:5560-5567, 2005
12. Bonner JA, Harari PM, Giralt J, et al: Radiotherapy plus cetuximab for locoregionally advanced squamous cell carcinoma of head and neck. N Engl J Med (in press)
13. Citron ML, Berry DA, Cirrincione C, et al: Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: First report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 21:1431-1439, 2003
14. Pfreundschuh M, Trumper L, Kloess M, et al: Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: Results of the NHL-B1 trial of the DSHNHL. Blood 104:626-633, 2004
15. Dy GK, Miller AA, Mandrekar SJ, et al: A phase II trial of imatinib (ST1571) in patients with c-kit expressing relapsed small-cell lung cancer: A CALGB and NCCTG study. Ann Oncol 16:1811-1816, 2005
16. Krug LM, Crapanzano JP, Azzoli CG, et al: Imatinib mesylate lacks activity in small cell lung carcinoma expressing c-kit protein: A phase II clinical trial. Cancer 103:2128-2131, 2005